CP1 E. Coli Immunotherapy for Low-Immunogenic Prostate Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immune checkpoint inhibitors have shown limited efficacy in treating prostate cancer due to low levels of tumor-infiltrating lymphocytes and innate immunogenicity, despite high PD-L1 expression and PD-1 positivity, necessitating new immunotherapeutic strategies.
Innovation Solution
Administration of uropathogenic bacteria, specifically CP1 E. coli, which invades and colonizes prostate tissue, inducing a T-cell inflammatory response, increasing production of pro-inflammatory biomarkers, and is genetically modified to express tumor-associated antigens, enhancing the efficacy of PD-1 blockade.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If immune checkpoint inhibitors are administered alone, then the treatment approach is simple, but the efficacy is limited due to low TIL levels and innate immunogenicity
Solution Approach 1:
The patent combines immune checkpoint inhibitors with uropathogenic bacteria (CP1 E. coli) to create a combination therapy. The bacteria serve as a biological vector that delivers immunogenic components directly to the tumor microenvironment, while the checkpoint inhibitor blocks immune suppression. This merging of two different therapeutic mechanisms overcomes the limitation of using checkpoint inhibitors alone, particularly in tumors with low immunogenicity like prostate cancer.
Solution Approach 2:
The uropathogenic bacteria act as an intermediary that bridges the gap between the checkpoint inhibitor and the tumor cells. The bacteria express tumor-associated antigens and stimulate the immune system to generate TILs, which then become responsive to checkpoint blockade. This intermediary approach solves the problem of low innate immunogenicity by introducing a biological agent that actively stimulates immune recognition.
2Reliability
If uropathogenic bacteria are used to increase TIL density and induce inflammatory response, then anti-tumor immunity is enhanced, but the treatment complexity increases
Solution Approach 1:
The uropathogenic bacteria are engineered to perform multiple functions simultaneously: they express tumor-associated antigens (PSA, PSCA), stimulate T-cell responses, produce pro-inflammatory cytokines (TNFα, IFNγ, IL-12), and recruit TILs to the tumor microenvironment. This multi-functionality consolidates what would otherwise require multiple separate therapeutic agents into a single biological vector, reducing overall treatment complexity while enhancing anti-tumor immunity.
Solution Approach 2:
The bacteria are genetically modified to alter key parameters of the tumor microenvironment: increasing TIL density, elevating pro-inflammatory cytokine levels, and changing the immunogenicity profile of the tumor. These parameter changes are achieved through genetic engineering of the bacteria to express specific antigens and cytokines, transforming the immunosuppressive microenvironment into a pro-inflammatory, immune-active environment that responds to checkpoint blockade.
3Reliability
If the tumor microenvironment is reprogrammed to a pro-inflammatory phenotype, then checkpoint blockade sensitivity increases, but the biological manipulation becomes more complex
Solution Approach 1:
The uropathogenic bacteria are administered to pre-condition the tumor microenvironment before checkpoint inhibitor therapy. The bacteria express tumor-associated antigens and stimulate the immune system in advance, generating TILs and creating a pro-inflammatory phenotype. This preliminary action ensures that when the checkpoint inhibitor is administered, the immune system is already primed and responsive, overcoming the typical resistance seen in tumors with low innate immunogenicity.
Solution Approach 2:
The engineered bacteria serve themselves by autonomously navigating to the tumor microenvironment, expressing the required antigens and cytokines, and stimulating the immune response without requiring external intervention. The bacteria's natural pathogenic properties are harnessed to deliver the therapeutic payload directly to the target site, reducing the need for complex delivery systems and external manipulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CP1 E. coli increases TIL density, skews the tumor microenvironment towards a pro-inflammatory phenotype, and synergistically enhances the efficacy of anti-PD-1 immunotherapy, reducing tumor burden and improving survival in prostate cancer models.
Implementation Method 1
administering uropathogenic bacteria capable of inducing T-cell inflammatory response in human or animal tissue
Implementation Method 2
increased production of biomarkers of inflammation including TNFα, IFNγ, IL-12, and CXCL9
Data Source
AI summary
Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.